SEC VERIFY DATA
Federal court deal over biotech funding. Learn how revenue proof, payer data, founder equity and due care can alter private company review.
BIOTECH FUNDING REVIEW
A federal court deal in late 2026 put biotech funding and revenue proof under legal review. The matter can help explain why payer data, growth claim, founder equity, billing method and due care all matter when private capital move into a young company. A real product and rapid revenue line can look compelling, yet headline growth alone cannot prove that the underlying payment model will endure. Independent review can remain vital before relying on a private company pitch.
https://www.sec.gov/enforcement-litigation/litigation-releases/lr-26641
On September 14, 2026, the U.S. Securities and Exchange Commission filed consents and proposed final judgments involving Jessica Richman and Zachary Apte, co-founders of uBiome, Inc., a San Francisco-based private medical testing company that ceased operations in 2019. The SEC originally sued Richman and Apte in March 2021, alleging that they misled investors during a private fundraising campaign by portraying uBiome as a rapidly growing biotechnology company with reliable health-insurance reimbursement and a proven business model. The proposed 2026 resolution does not constitute an admission of the SEC's allegations. Subject to court approval, Richman and Apte each agreed to a $125,000 civil penalty, a three-year officer-and-director bar and a three-year prohibition on participating in the issuance, purchase, offer or sale of securities other than transactions for their own personal accounts.
The case provides an unusually useful framework for private-company due diligence because the core investment story contained elements that appeared highly attractive: rapid revenue growth, an emerging biotechnology market, recognizable institutional funding, health-insurance reimbursement and a valuation approaching $600 million. According to the SEC complaint, however, material weaknesses existed beneath those headline metrics. The Commission alleges that the company's revenue depended heavily on billing practices that insurers were already challenging and that investors were not given an accurate picture of those risks before committing capital.
REVENUE GROWTH DOES NOT ALWAYS MEAN REVENUE QUALITY
Private-company investors often focus heavily on growth.
A startup reporting rapidly increasing revenue may receive a higher valuation because investors assume the company has demonstrated product-market fit, customer demand and a scalable business model.
But revenue quality can matter as much as revenue quantity.
A company may record revenue that later proves difficult to collect, subject to refund, dependent on disputed billing practices or vulnerable to regulatory intervention.
According to the SEC complaint, Richman and Apte promoted uBiome's Series C round from approximately May through September 2018. The offering valued the company at nearly $600 million and raised approximately $59 million through preferred-stock sales to roughly 27 investors.
During the same period, approximately six investors also purchased more than $2 million of convertible promissory notes.
Those figures illustrate the scale of the financing.
But the more important diligence question was whether the revenue supporting the valuation was durable.
The SEC alleges that investors were told uBiome had developed a successful business based in part on reliable reimbursement from health insurers for clinical microbiome testing.
According to the Commission, that picture did not adequately disclose that insurers had challenged the company's billing practices and that part of the reported revenue depended on practices vulnerable to rejection or clawback.
For private-market investors, the lesson is broader than healthcare.
Revenue should be evaluated according to its economic quality.
A strong diligence process can distinguish among revenue that has been invoiced, revenue that has been collected, revenue that remains subject to dispute, and revenue that could later be reversed.
THE 900% GROWTH CLAIM DESERVED DEEPER VERIFICATION
The SEC complaint describes particularly aggressive growth claims.
According to the complaint, Richman told potential Series C investors in July 2018 that uBiome had achieved revenue growth of almost 900% since June 2017 and projected more than $100 million of total revenue for 2018.
Those numbers would naturally attract investor attention.
A company increasing revenue nearly tenfold can appear to have reached an inflection point.
But extraordinary growth generally warrants extraordinary verification.
Investors evaluating a private company should understand not only how fast revenue increased but why.
Growth driven by repeat demand from independent customers is different from growth driven by aggressive billing assumptions, unusual transaction structures or practices that may not survive regulatory or counterparty review.
In healthcare, reimbursement quality can be especially important because reported revenue may ultimately depend on medical necessity, billing codes, insurer policies and documentation.
The SEC alleges that uBiome represented to investors that its clinical tests were covered by existing insurance billing codes and current health-plan guidelines.
According to the complaint, however, the defendants knew or were reckless in not knowing that the company used incorrect or varying billing codes to obtain reimbursement.
That allegation turns a normal growth question into a diligence question about the durability of the entire revenue engine.
INSURANCE REIMBURSEMENT SHOULD BE TESTED INDEPENDENTLY
Healthcare startups can produce impressive revenue numbers when insurers reimburse expensive clinical products or tests.
But reimbursement is not equivalent to ordinary cash sales.
The investor needs to understand whether the payer accepts the billing method, whether the treatment or test meets coverage criteria and whether previously paid claims can be challenged later.
The SEC alleges that insurers ultimately sought clawbacks of prior payments to uBiome.
That concept is important.
Revenue already recorded in financial statements can lose economic value if counterparties later demand repayment.
For a private-company investor, payer concentration and reimbursement disputes can therefore be as important as topline growth.
A deeper review can examine historical denial rates, appeals, reimbursement policies, payer correspondence, reserve methodology and any significant disputes with insurers.
Investors should also distinguish between management's interpretation of reimbursement rules and independent legal or compliance confirmation.
When a company's valuation depends heavily on a particular billing model, that model deserves transaction-level diligence.
CUSTOMER AND DOCTOR NETWORK CLAIMS CAN ALSO REQUIRE VERIFICATION
The SEC complaint alleges that uBiome's business depended in part on medical-test orders from doctors.
According to the Commission, investors were reassured that the company's doctor network exceeded regulatory standards and had been reviewed by counsel.
The SEC alleges that the reality was more complicated and that legal concerns about the network and billing model had been raised internally.
This provides another private-market diligence lesson.
Statements that a business has been "reviewed by counsel," "approved by experts," or "validated by doctors" can create confidence, but the scope of that validation matters.
A lawyer may review one aspect of a program while raising concerns about another.
A physician may participate in a network without independently validating every business practice.
Investors should therefore avoid converting a narrow professional relationship into a broad endorsement.
The strongest evidence comes from understanding exactly what was reviewed, who performed the review and whether material qualifications or warnings were omitted from the investor presentation.
INTERNAL WARNINGS CAN BE HIGH-VALUE DUE-DILIGENCE EVIDENCE
The SEC complaint states that uBiome employees raised concerns about billing practices during the fundraising period.
According to the Commission, management did not adequately disclose those concerns to investors and instead acted to conceal certain practices from insurers, the board and the company's general counsel.
Internal warnings can be especially important in private-company diligence because public information is limited.
A private company's investor presentation is generally prepared by the same management team seeking capital.
That creates an information imbalance.
Institutional investors can reduce that imbalance by requesting access to board materials, legal diligence, customer references, compliance reports and key operational personnel rather than relying entirely on the executive team.
Not every employee complaint is accurate.
But a repeated warning concerning a business process that generates a large portion of company revenue should ordinarily receive additional investigation.
The same principle applies outside healthcare.
A fintech company may receive internal warnings about transaction monitoring.
A private-credit platform may receive warnings about underwriting quality.
A software company may receive warnings about customer churn.
The important question is whether the investor process is capable of discovering information that conflicts with management's fundraising narrative.
FOUNDER SECONDARY SALES CHANGE THE INCENTIVE ANALYSIS
The uBiome Series C financing also included founder liquidity.
According to the SEC complaint, Richman sold approximately $5 million of personally owned uBiome stock in connection with the fundraising round.
Apte also sold approximately $5 million of his personally owned shares.
Founder secondary sales are not inherently problematic.
Private-company founders may reasonably seek partial liquidity after building a company for many years.
But the size and timing of a secondary sale matter to investors because they change incentives.
When a founder sells substantial personal holdings during the same round in which new investors are purchasing shares based on strong growth projections, diligence should examine whether the information available to both sides is symmetrical.
Investors should know the amount of founder liquidity, the valuation applied to secondary shares, whether the founder retains meaningful ownership after the transaction and whether material business risks were disclosed.
A primary financing puts capital into the company.
A secondary sale puts capital into the seller's hands.
Those economic effects are different even when both occur in the same financing round.
PRIVATE COMPANY VALUATION SHOULD BE RECONSTRUCTED FROM THE BUSINESS MODEL
A valuation near $600 million can appear authoritative when supported by sophisticated investors and formal financing documents.
But private valuations are negotiated prices.
They do not provide the same continuous price discovery found in public markets.
The appropriate diligence therefore works backward from the valuation.
Investors can examine revenue multiples, gross margin, cash collection, growth assumptions, customer concentration, regulatory risk and the amount of additional capital required to reach profitability.
For a company relying heavily on insurance reimbursement, the quality of that reimbursement should directly affect valuation.
If the revenue base is less durable than expected, the implied multiple can quickly become much higher than investors originally believed.
This is why valuation and business-model diligence should be connected rather than treated as separate workstreams.
A company cannot be valued accurately without understanding how it earns money.
BOARD OVERSIGHT CAN BECOME CRITICAL BEFORE A CRISIS
The SEC complaint states that uBiome's board initiated an internal investigation in April 2019 following the FBI's execution of a search warrant at the company's San Francisco headquarters.
According to the SEC, the investigation brought improper billing practices to light.
uBiome subsequently suspended its clinical testing business, ceased operations in September 2019 and entered bankruptcy.
The sequence illustrates how rapidly private-company value can change once a critical business assumption fails.
An investor may hold preferred stock in a company valued at hundreds of millions of dollars, yet private shares can lose most or all of their economic value if the operating model collapses.
Board oversight is therefore not merely a governance formality.
Investors should understand who sits on the board, what information directors receive, whether major compliance issues are escalated and how quickly investigations begin when material warnings emerge.
A well-known venture investor on the capitalization table does not eliminate the need for independent review.
BANKRUPTCY RISK IS DIFFERENT FOR PRIVATE EQUITY HOLDERS
When a startup enters bankruptcy, equity investors generally sit behind creditors in the capital structure.
Preferred shareholders may have contractual preferences over common shareholders, but those preferences only have value if sufficient assets remain after creditor claims.
That makes downside analysis important even during high-growth fundraising rounds.
Investors should understand liquidation preferences, senior debt, convertible notes, secured obligations and any other claims ranking ahead of their equity.
The uBiome case illustrates why headline valuation should not be confused with recoverable value.
A private company can move from a high fundraising valuation to insolvency in a relatively short period when the assumptions supporting its business deteriorate.
PROPOSED 2026 SETTLEMENT CHANGES THE PROCEDURAL STATUS
The September 2026 SEC release is important because the case is no longer merely at the complaint stage.
On September 14, 2026, Richman and Apte consented to proposed final judgments, subject to court approval.
Neither admitted the allegations.
The proposed judgments would permanently enjoin both defendants from future violations of Securities Act Section 17(a), Exchange Act Section 10(b) and Rule 10b-5.
Each defendant would also pay a $125,000 civil penalty.
Both would receive three-year officer-and-director bars.
They would additionally be prohibited for three years from participating in the issuance, purchase, offer or sale of securities, except for transactions in their own personal accounts.
This procedural status should be described precisely.
The original allegations remain allegations.
The defendants have agreed to a settlement structure without admitting them.
The proposed judgments still require court approval.
WHY THIS MATTERS BEYOND BIOTECH
The most useful lesson from the uBiome case is broader than medical testing.
Many private-company financings rely on a narrative built around a few headline metrics.
Revenue growth.
Customer count.
Market size.
Recurring income.
Strategic partnerships.
Regulatory approval.
Investor quality.
Those metrics can be real while still presenting an incomplete picture.
Private-market diligence should therefore examine the mechanisms underneath the metric.
If revenue is growing rapidly, identify the customer and payment source.
If recurring revenue is highlighted, examine churn and collectability.
If regulatory compliance is important, review the underlying legal framework.
If a founder is selling stock, understand the amount and incentive effect.
If a valuation is very high, reconstruct the assumptions required to justify it.
FILINGDOSSIER INDEPENDENT ANALYSIS
The uBiome litigation offers a useful model for private-company verification because the underlying company was not imaginary.
It had real products, employees, investors, financing rounds and reported revenue.
The SEC's allegations instead focus on the quality and sustainability of the business information presented during fundraising.
That distinction matters.
Private-company fraud risk does not always begin with fabricated assets.
It can arise when real business activity is presented without material information needed to understand whether the growth is durable.
In the uBiome Series C round, the SEC alleges that investors received a compelling story of rapid expansion and reliable insurance reimbursement while important risks surrounding billing practices were not adequately disclosed.
At the same time, the founders sold approximately $10 million of their own shares in the round.
For FilingDossier research, the case supports a broader diligence principle: a private-company fundraising review should connect financial metrics with operational evidence.
Revenue should connect to cash collection.
Cash collection should connect to a sustainable customer or payer relationship.
Valuation should connect to durable economics.
Founder liquidity should be considered alongside the information available to new investors.
And regulatory or legal warnings should be evaluated before they become existential problems.
KEY FINDINGS
The SEC announced a proposed settlement with uBiome co-founders Jessica Richman and Zachary Apte on September 16, 2026.
The original SEC complaint was filed on March 18, 2021.
uBiome was a San Francisco-based private medical testing company.
The SEC originally described the case as involving approximately $60 million in investor funding.
The complaint states that the Series C round raised approximately $59 million from roughly 27 preferred-stock investors.
Approximately six additional investors purchased more than $2 million of convertible promissory notes during the same period.
The Series C financing valued uBiome at nearly $600 million.
According to the SEC complaint, Richman promoted revenue growth of almost 900% since June 2017.
The complaint also states that investors were told uBiome could generate more than $100 million in total 2018 revenue.
The SEC alleges that material risks involving health-insurance reimbursement and billing practices were not adequately disclosed.
The SEC alleges that insurers later sought repayment of prior reimbursements.
Richman sold approximately $5 million of personally owned uBiome shares during the Series C round.
Apte also sold approximately $5 million of personally owned shares.
uBiome suspended its clinical testing business in 2019 and later ceased operations and entered bankruptcy.
Under the proposed 2026 resolution, Richman and Apte would each pay a $125,000 civil penalty.
Each would also receive a three-year officer-and-director bar and a three-year securities-transaction participation restriction, subject to stated exceptions.
CASE SNAPSHOT
Company: uBiome, Inc. Co-Founder and Former CEO: Jessica Richman Co-Founder and Former Chief Scientific Officer: Zachary Apte SEC Litigation Release: No. 26641 Latest SEC Release Date: September 16, 2026 Proposed Settlement Filed: September 14, 2026 Original SEC Complaint Date: March 18, 2021 Original Litigation Release: No. 25056 Original SEC Press Release: 2021-49 Court: U.S. District Court for the Northern District of California Case Number: 3:21-cv-01911-CRB Series C Period: Approximately May through September 2018 Series C Capital Raised: Approximately $59 million Preferred-Stock Investors: Approximately 27 Convertible Notes: More than $2 million Convertible-Note Investors: Approximately 6 Series C Valuation: Nearly $600 million Founder Secondary Sales: Approximately $5 million each by Richman and Apte Business Outcome: Operations ceased in 2019 and company entered bankruptcy Proposed Civil Penalty: $125,000 for each defendant Proposed Officer-and-Director Bar: Three years for each defendant Proposed Securities Participation Restriction: Three years Admission Status: Defendants consented without admitting SEC allegations Court Approval: Proposed final judgments remain subject to court approval Primary Research Lesson: Verify revenue quality, payer economics, founder liquidity and operational risk behind private-company growth claims